Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using Single Photon Emission Computed Tomography-Computed Tomography (SPECT-CT) imaging (original) (raw)

“…Finally, primary resistance to chemotherapy in pancreatic cancer may be more prevalent. To explore these possibilities, a companion imaging study (NCT01832116) using PET with the anti-mesothelin antibody conjugated to zirconium-89 was conducted, which demonstrated that primary pancreatic tumors accumulated less antibody than their respective metastases, whereas uptake was similar between ovarian tumors and their metastases (note: n ¼ 3 and n ¼ 2) consistent with previously published data (33). These preliminary observations suggest that relatively poor ADC uptake may be more relevant than primary resistance of pancreatic tumors (34).…”

Section: Discussionsupporting

“…Finally, primary resistance to chemotherapy in pancreatic cancer may be more prevalent. To explore these possibilities, a companion imaging study (NCT01832116) using PET with the anti-mesothelin antibody conjugated to zirconium-89 was conducted, which demonstrated that primary pancreatic tumors accumulated less antibody than their respective metastases, whereas uptake was similar between ovarian tumors and their metastases (note: n ¼ 3 and n ¼ 2) consistent with previously published data (33). These preliminary observations suggest that relatively poor ADC uptake may be more relevant than primary resistance of pancreatic tumors (34).…”

Section: Discussionsupporting

“…study, in 4 patients with mesothelioma and 2 patients with pancreatic cancer. Here, 4 mCi 111 In-labeled MSLN antibody amatuximab was administered and subsequent SPECT showed uptake in pancreatic cancer lesions but a higher uptake in mesothelioma lesions (51).…”

Section: Discussionmentioning

“…Biodistribution and dosimetry of 111 In-amatuximab in 6 patients with mesothelin-expressing cancers (4 with malignant mesothelioma and 2 with pancreatic adenocarcinoma) was recently evaluated using Single Photon Emission Computed Tomography-Computed Tomography (SPECT-CT) imaging [26]. 111 In-amatuximab targeted mesothelin-expressing cancer cells, with a clinically meaningful uptake in both primary tumors and metastatic sites of both tumor types, although a higher uptake was noted in mesothelioma than pancreatic cancer.…”

Section: Novel Antibody Therapeutics Targeting Mesothlin As Cancer Drmentioning